



Aclaris Therapeutics to Attend Upcoming Investor Conferences

January 2, 2019

WAYNE, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology and immunology, today announced that management will attend the following conferences:

- Management will host investor meetings during the 2019 JP Morgan Healthcare Conference in San Francisco, CA from Monday, January 7, 2019 through Wednesday, January 9, 2019.
- Dr. Neal Walker, President and Chief Executive Officer, will present at the 8th Annual Leerink Partners Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 10:30 AM EST. Management will also host investor meetings on Wednesday, February 27, 2019.

A live webcast of the 8th Annual Leerink Partners Global Healthcare Conference presentation may be accessed through the Company's web site, www.aclaristx.com, on the 'Events and Presentations' section. An archived version of the presentation will be available for 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Contact:

Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
mtung@aclariastx.com

Media Contact
Sheila Kennedy
Vice President, Corporate Communications
484-321-5559
media@aclariastx.com



Source: Aclaris Therapeutics, Inc.